InQuery vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
InQuery logo

InQuery

EmergingHealthcare

General

SF YC W24 AI medical record review for health insurance prior auth and claims; $3.1M from General Catalyst/DRW/YC deploying AI agents that process clinical documentation for coverage decisions competing with Cohere Health.

AI VisibilityBeta
Overall Score
C40
Category Rank
#378 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
36
Gemini
38

About

InQuery is a San Francisco-based AI healthcare platform — backed by Y Combinator (W24) with $3.1 million in total funding from Y Combinator, General Catalyst, Amino Capital, and DRW Venture Capital — providing health insurance companies and managed care organizations with AI agents that autonomously review medical records, analyze clinical documentation, and process prior authorization and claims decisions at a speed and scale that human reviewers cannot match. Founded in 2023, InQuery applies large language models trained on clinical documentation to the insurance review workflows that currently require teams of nurses and physician advisors to manually read through hundreds of pages of medical records per case.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#378
Category Rank
#2
77
AI Consensus
83
stable
Trend
stable
41
ChatGPT
92
36
Perplexity
93
38
Gemini
89
36
Claude
96
45
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.